The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy

Nieder,Carsten; Mannsåker,Bård; Dalhaug,Astrid; Pawinski,Adam; Haukland,Ellinor

doi:10.3892/mco.2017.1228

The Glasgow prognostic score: Useful information when prescribing palliative radiotherapy

Authors:
- Carsten Nieder
- Bård Mannsåker
- Astrid Dalhaug
- Adam Pawinski
- Ellinor Haukland
View Affiliations

Affiliations: Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, N-9037 Tromsø, Norway, Department of Oncology and Palliative Medicine, Nordland Hospital, N-8092 Bodø, Norway
Published online on: April 26, 2017 https://doi.org/10.3892/mco.2017.1228
Pages: 811-816
Copyright: © Nieder et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of the present retrospective study was to investigate whether a score reflecting systemic inflammatory processes [the Glasgow Prognostic Score (GPS)] provides relevant information for radiation oncologists. GPS is a three‑tiered score [0: normal C-reactive protein (CRP) and albumin; 1: one abnormal result; 2: increased CRP and low albumin]. Correlations between disease type and extent, resource utilization, survival and GPS were analyzed in 703 patients. In the subgroup with GPS 2, significantly higher rates of lung, adrenal gland and liver metastases were observed. An increasing GPS score was associated with a higher likelihood of anemia, leukocytosis and thrombocytosis. Comparable findings were made regarding utilization of palliative care resources, need for blood transfusion and intravenous administration of antibiotics. Compared with GPS 0 or 1, more patients with GPS 2 did not complete their prescribed course of radiotherapy. One-third of patients with GPS 2 received treatment during the final month of life. Multivariate analysis demonstrated that GPS was a significant prognostic factor for overall survival (median, 479, 136, and 61 days, for GPS 0, 1 and 2, respectively). In patients with GPS 2 and additional leukocytosis, the median survival was 38 days. In conclusion, GPS provides important prognostic information. This biomarker-based score may be considered for deciding fractionation, and should be validated further.

View Figures

View References

1	Tseng YD, Krishnan MS, Sullivan AJ, Jones JA, Chow E and Balboni TA: How radiation oncologists evaluate and incorporate life expectancy estimates into the treatment of palliative cancer patients: A survey-based study. Int J Radiat Oncol Biol Phys. 87:471–478. 2013. View Article : Google Scholar : PubMed/NCBI
2	Likhacheva A, Pinnix CC, Parikh NR, Allen PK, McAleer MF, Chiu MS, Sulman EP, Mahajan A, Guha-Thakurta N, Prabhu SS, et al: Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys. 85:656–661. 2013. View Article : Google Scholar : PubMed/NCBI
3	Forrest LM, McMillan DC, McArdle CS, Angerson WJ and Dunlop DJ: Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 90:1704–1706. 2004.PubMed/NCBI
4	Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: A Glasgow Inflammation Outcome Study. Br J Cancer. 104:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
5	Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 47:2633–2641. 2011. View Article : Google Scholar : PubMed/NCBI
6	Linton A, Pond G, Clarke S, Vardy J, Galsky M and Sonpavde G: Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer. 11:423–430. 2013. View Article : Google Scholar : PubMed/NCBI
7	Guadagnolo BA, Liao KP, Elting L, Giordano S, Buchholz TA and Shih YC: Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol. 31:80–87. 2013. View Article : Google Scholar : PubMed/NCBI
8	Murphy JD, Nelson LM, Chang DT, Mell LK and Le QT: Patterns of care in palliative radiotherapy: A population-based study. J Oncol Pract. 9:e220–e227. 2013. View Article : Google Scholar : PubMed/NCBI
9	Kapadia NS, Mamet R, Zornosa C, Niland JC, D'Amico TA and Hayman JA: Radiation therapy at the end of life in patients with incurable nonsmall cell lung cancer. Cancer. 118:4339–4345. 2012. View Article : Google Scholar : PubMed/NCBI
10	Kelly CM and Shahrokni A: Moving beyond Karnofsky and ECOG performance status assessments with new technologies. J Oncol. 2016:61865432016. View Article : Google Scholar : PubMed/NCBI
11	Hahn C, Kavanagh B, Bhatnagar A, Jacobson G, Lutz S, Patton C, Potters L and Steinberg M: Choosing wisely: The American Society for Radiation Oncology's top 5 list. Pract Radiat Oncol. 4:349–355. 2014. View Article : Google Scholar : PubMed/NCBI
12	Olson RA, Tiwana MS, Barnes M, Kiraly A, Beecham K, Miller S, Hoegler D and Olivotto I: Use of single- versus multiple-fraction palliative radiation therapy for bone metastases: Population-based analysis of 16,898 courses in a Canadian province. Int J Radiat Oncol Biol Phys. 89:1092–1099. 2014. View Article : Google Scholar : PubMed/NCBI
13	Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, Bhatt A, Jensen AW, Brown PD, Shih H, et al: Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 77:655–661. 2010. View Article : Google Scholar : PubMed/NCBI
14	Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 37:745–751. 1997. View Article : Google Scholar : PubMed/NCBI
15	Partl R, Richtig E, Avian A, Berghold A and Kapp KS: Karnofsky performance status and lactate dehydrogenase predict the benefit of palliative whole-brain irradiation in patients with advanced intra- and extracranial metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 85:662–666. 2013. View Article : Google Scholar : PubMed/NCBI
16	Tan CS, Read JA, Phan VH, Beale PJ, Peat JK and Clarke SJ: The relationship between nutritional status, inflammatory markers and survival in patients with advanced cancer: A prospective cohort study. Support Care Cancer. 23:385–391. 2015. View Article : Google Scholar : PubMed/NCBI
17	Anshushaug M, Gynnild MA, Kaasa S, et al: Characterization of patients receiving palliative chemo- and radiotherapy during end of life at a regional cancer center in Norway. Acta Oncol. 27:1–8. 2014.
18	Leung EY, Scott HR and McMillan DC: Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol. 7:655–662. 2012. View Article : Google Scholar : PubMed/NCBI
19	Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P and Klepstad P: Prognostic factors in patients with advanced cancer: A comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 19:5456–5464. 2013. View Article : Google Scholar : PubMed/NCBI
20	Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuyama Y, Ogawa M, Ishida Y, Misawa T and Yanaga K: The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett. 4:324–328. 2012.PubMed/NCBI
21	Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, Makridou M, Kakalou D and Georgoulias V: The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung Cancer. 77:383–388. 2012. View Article : Google Scholar : PubMed/NCBI
22	Angelo K, Norum J, Dalhaug A, Pawinski A, Aandahl G, Haukland E, Engljähringer K and Nieder C: Development and validation of a model predicting short survival (death within 30 days) after palliative radiotherapy. Anticancer Res. 34:877–885. 2014.PubMed/NCBI
23	Gripp S, Mjartan S, Boelke E and Willers R: Palliative radiotherapy tailored to life expectancy in end-stage cancer patients: Reality or myth? Cancer. 116:3251–3256. 2010. View Article : Google Scholar : PubMed/NCBI
24	Nieder C, Angelo K, Dalhaug A, Pawinski A, Haukland E and Norum J: Palliative radiotherapy during the last month of life: Predictability for referring physicians and radiation oncologists. Oncol Lett. 10:3043–3049. 2015.PubMed/NCBI
25	Proctor MJ, Horgan PG, Talwar D, Fletcher CD, Morrison DS and McMillan DC: Optimization of the systemic inflammation-based Glasgow prognostic score: A Glasgow Inflammation Outcome Study. Cancer. 119:2325–2332. 2013. View Article : Google Scholar : PubMed/NCBI